SCHEMBL17437

SCHEMBL17437

O=S(=O)(c1ccccc1)c1ccc(-c2ccc(O)cc2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.53
GAA P10253 1/20 0.53
GFER P55789 1/20 0.53
HTR6 P50406 1/20 0.50
HSD11B1 P28845 5/20 0.47
ESR2 Q92731 2/20 0.46
ABCC9 O60706 1/20 0.45
ABCC8 Q09428 1/20 0.45
KCNJ11 Q14654 1/20 0.45
KCNJ8 Q15842 1/20 0.45
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ERAP1 Q9NZ08 1/20 0.43
MMP3 P08254 2/20 0.42
BCL2L1 Q07817 1/20 0.42
KIF18A Q8NI77 1/20 0.42
UQCRB P14927 1/20 0.42
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16990 0.82 POLB (0.44) POLBGAAGFERHTR6HSD11B1
SCHEMBL2909430 0.81 HSD11B1 (0.63) HTR6HSD11B1
SCHEMBL10454872 0.80 POLB (0.59) POLBGAAGFERHSD11B1
SCHEMBL15979 0.78 HSD11B1 (0.77) HSD11B1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL17847 0.78 HSD11B1 (0.77) HSD11B1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL16670 0.78 HSD11B1 (0.77) HSD11B1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL12093428 0.78 HTR6 (0.50) POLBGAAGFERHTR6HSD11B1
SCHEMBL7935388 0.77 HTR6 (0.61) POLBGAAGFERHTR6ESR2
SCHEMBL1992954 0.76 POLB (0.44) POLBGAAGFERHSD11B1ESR2
SCHEMBL9635238 0.76 HSD11B1 (0.65) POLBGAAGFERHSD11B1ABCC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 POLB 4613/4885GAA 455/4885GFER 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.